BSA PHARMACEUTICALS
The computed 12-month bankruptcy probability of BSA PHARMACEUTICALS is 5.6% (elevated). The 2024 annual accounts show negative equity (€-396k) and a net result of €-61k. Equity is shrinking by ~84.2% per year across the filed fiscal years. Its solvency ranks better than 5% of 549 sector peers (fiscal year 2024). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €-396k |
| Net result | €-61k |
| Better than sector | 5% |
| Active | 5 yrs |
Mixed profile: strong on stability, weaker on health.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -351.2% | 31.0% | |
| Net result | €-61k | €47k | |
| Equity | €-396k | €468k | |
| Gross operating margin | €-31k | €125k | |
| Total assets | €113k | €1.82M |
Show 8 other metrics
| Fiscal year | 2024 |
|---|---|
| Deposit | volledig |
| Revenue | - |
| EBITDA | €-33k |
| Net profit | €-61k |
| Cash flow | €-34k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €113k |
| Equity | €-396k |
| Debt | €509k |
| of which ≤ 1y | €509k |
| of which > 1y | - |
| Working capital | €-396k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 0.22 |
| Quick ratio | 0.22 |
| Working capital ratio | -351.2% |
| Solvency | -351.2% |
| Debt / equity | -1.28 |
| Long-term debt ratio | - |
| Interest coverage | -39.16 |
| Gross margin | - |
| Net margin | - |
| ROA | -54.0% |
| ROE | 15.4% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (19 line items)
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €113k |
| Intangible fixed assets | 21 | €0 |
| Current assets | 29/58 | €113k |
| Amounts receivable within one year | 40/41 | €108k |
| Cash & bank | 54/58 | €4k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €113k |
| Equity | 10/15 | €-396k |
| Contributions / capital | 10/11 | €20k |
| Accumulated profits (losses) | 14 | €-416k |
| Amounts payable | 17/49 | €509k |
| Amounts payable within one year | 42/48 | €509k |
| Trade debts payable within one year | 44 | €295k |
| Income statement | ||
| Gross operating margin | 9900 | €-31k |
| Operating result | 9901 | €-61k |
| Financial income | 75 | €704 |
| Financial charges | 65 | €853 |
| Result before taxes | 9903 | €-61k |
| Net result for the period | 9904 | €-61k |
| Result to be appropriated | 9905 | €-61k |
| NACE primary | Handelsbemiddeling in de groothandel in andere specifieke goederen(46180) |
| Legal form | Private limited company(610) |
| Incorporation | 14-12-2020 |
| Status | Active |
| Postal code | 1050 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21807G0131/00T000 | Brussels | 5,672 m² | 1 · 3,878 m² | 45.8 m · 8 fl. |
| 21822R0226/00W011 | Brussels | 3,529 m² | 1 · 1,878 m² | 38.1 m · 7 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
Of the 2 Belgian State Gazette acts we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.
18-08-2026 Act object · Board meeting · Seat change · Filing representative
- Act object: Transfert de siège social · BSA Pharmaceuticals
- Publication: 2026-08-18 · BSA Pharmaceuticals
- Filing: 2026-08-11 · BSA Pharmaceuticals
- Board meeting: 2026-05-27 · BSA Pharmaceuticals
- Seat change: to: 1050 Bruxelles, Avenue Louise, 213, from: 1050 Bruxelles, Avenue Louise, 523, effective_date: 2026-07-01 · BSA Pharmaceuticals
- Filing representative: accomplir toutes les formalités de publication et de dépôt requises auprès du greffe du Tribunal de l'entreprise compétent, de la Banque- Carrefour des Entreprises, ainsi que pour la publication aux Annexes du Moniteur belge · Alfred Guyot
Technical details
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Transfert de si\u00E8ge social",
"value": "Transfert de si\u00E8ge social",
"object": null,
"subject": "e1"
},
{
"date": "2026-08-18",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 18/08/2026 - Annexes du Moniteur belge",
"value": "2026-08-18",
"object": null,
"subject": "e1"
},
{
"date": "2026-08-11",
"type": "filing",
"quote": "D\u00E9pos\u00E9 / Re\u00E7u le 11 AOUT 2026 au greffe du trihunal de l\u0027entreprise francophone de Bruxelles",
"value": "2026-08-11",
"object": null,
"subject": "e1"
},
{
"date": "2026-05-27",
"type": "board_meeting",
"quote": "DECISION DE L\u0027ADMINISTRATEUR UNIQUE, de la soci\u00E9t\u00E9 BSA Pharmaceuticals S.r.l., en date du 27 Mai 2026",
"value": "2026-05-27",
"object": null,
"subject": "e1"
},
{
"date": "2026-07-01",
"type": "seat_change",
"quote": "Le si\u00E8ge social de la soci\u00E9t\u00E9 est transf\u00E9r\u00E9 de l\u0027adresse actuelle: 1050 Bruxelles, Avenue Louise, 523, vers la nouvelle adresse suivante: 1050 Bruxelles, Avenue Louise, 213, avec effet au 1er Juillet 2026.",
"value": {
"to": "1050 Bruxelles, Avenue Louise, 213",
"from": "1050 Bruxelles, Avenue Louise, 523",
"effective_date": "2026-07-01"
},
"object": null,
"subject": "e1"
},
{
"type": "filing_representative",
"quote": "L\u0027administrateur unique donne mandat \u00E0 Mr Alfred Guyot, pour accomplir toutes les formalit\u00E9s de publication et de d\u00E9p\u00F4t requises aupr\u00E8s du greffe du Tribunal de l\u0027entreprise comp\u00E9tent, de la Banque- Carrefour des Entreprises, ainsi que pour la publication aux Annexes du Moniteur belge.",
"value": "accomplir toutes les formalit\u00E9s de publication et de d\u00E9p\u00F4t requises aupr\u00E8s du greffe du Tribunal de l\u0027entreprise comp\u00E9tent, de la Banque- Carrefour des Entreprises, ainsi que pour la publication aux Annexes du Moniteur belge",
"object": "e1",
"subject": "e2"
}
],
"act_meta": {
"outcome": "clean",
"model_id": 53,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1807,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0759.755.270",
"kind": "company",
"name": "BSA Pharmaceuticals",
"attrs": {
"seat": "Avenue Louise, 523 - 1050 Ixelles/Bruxelles",
"legal_form": "Srl"
}
},
{
"id": "e2",
"kbo": null,
"kind": "person",
"name": "Alfred Guyot",
"attrs": {}
}
]
}| Legal nameFR | BSA PHARMACEUTICALS |